Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL, in patients with cancer

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 6, 2014, Pages 680-684

  Yang, J ^a   Pradhan, R S ^b   Rosen, L S ^c   Graham, A M ^a   Holen, K D ^a   Xiong, H ^a  

^a ABBVIE INC   (United States)

^b ALEXION PHARMACEUTICALS   (United States)

^c Santa Monica UCLA Medical Center   (United States)

Author keywords

Bcl 2 inhibitor; CYP3A inducer; Drug interaction; Navitoclax; Pharmacokinetics; Rifampin

Indexed keywords

NAVITOCLAX; PROTEIN BCL 2; PROTEIN BCL XL; RIFAMPICIN; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; CYTOCHROME P450 3A INDUCER; PROTEIN BCL X; SULFONAMIDE;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CELLULITIS; CLINICAL ARTICLE; COLON CANCER; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NON SMALL CELL LUNG CANCER; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIMARY TUMOR; RHINOPHARYNGITIS; SMALL CELL LUNG CANCER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INTERACTION; HALF LIFE TIME; METABOLISM; MIDDLE AGED; NEOPLASMS; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BCL-X PROTEIN; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INDUCERS; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RIFAMPIN; SULFONAMIDES;

EID: 84912101900     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12193     Document Type: Article

References (20)

1. Droin N, Guery L, Benikhlef N, Solary E. Targeting apoptosis proteins in hematological malignancies. Cancer Lett, 2013;332:325-334.
2. Tomek M, Akiyama T, Dass CR. Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy. J Pharm Pharmacol, 2012;64:1695-1702.
3. Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol, 2012; 30:3127-3135.
4. Tse C, Shoemaker AR, Adickes J et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res, 2008;68:3421-3428.
5. Wilson WH, O'Connor OA, Czuczman MS et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol, 2010;11:1149-1159.
6. Gandhi L, Camidge DR, Ribeiro de Oliveira M et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients withsmall-cell lung cancer and other solid tumors. J Clin Oncol, 2011;29:909-916.
7. Roberts AW, Seymour JF, Brown JR et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol, 2012;30:488-496.
8. Serby M, Ahmed T, Yang J, Xiong H, Lee A, Shen J (2013) Metabolism and disposition of ABT-263 in humans. Paper presented at the Great Lakes drug metabolism discussion group annual meeting, Toledo, OH, May 9-10.
9. FDA Guidance for Industry (Draft). Drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations, 2012. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064982.htm (accessed 26 February 2014).
10. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther, 1996;59:7-13.
11. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther, 2000;68:592-597.
12. Benet LZ. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci, 2013;102:34-42.
13. Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J, 2011;13:519-547.
14. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet, 2003;42:819-850.
15. Goodwin B, Redinbo MR, Kliewer SA. Regulation of cyp3a gene transcription by the pregnane x receptor. Annu Rev Pharmacol Toxicol, 2002;42:1-23.
16. Lemmen J, Tozakidis IE, Galla HJ. Pregnane X receptor upregulates ABC-transporter Abcg2 and Abcb1 at the blood-brain barrier. Brain Res, 2013;1491:1-13.
17. Liu CL, Lim YP, Hu ML. Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells. Mar Drugs, 2012;10:242-257.
18. Cho SK, Yoon JS, Lee MG et al. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther, 2011;89:416-421.
19. Sugatani J, Uchida T, Kurosawa M, Yamaguchi M, Yamazaki Y, Ikari A, Miwa M. Regulation of pregnane X receptor (PXR) function andUGT1A1gene expression by posttranslational modification of PXR protein. Drug Metab Dispos, 2012;40:2031-2040.
20. Vogler M, Dickens D, Dyer MJ, Owen A, Pirmohamed M, Cohen GM. The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochem Biophys Res Commun, 2011;408:344-349.